Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Cardiologists have raised this question after the disappointing results of the phase 3 OCEANIC-AF trial, in which the anti-XI peptide asundexian (Bayer) failed to demonstrate efficacy, leading to ...

Bayer AG (BAYRY) reports modest sales growth and debt reduction amid financial headwinds and strategic challenges.

What Now for Factor XI Inhibitors in AF? Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the OCEANIC-AF trial, but is the ...